New antibiotics to draw interest for ophthalmologists

With the recent FDA approvals of fourth-generation fluoroquinolones,ophthalmologists now have two new antibiotics to fight bacteria in the eye.Moxifloxacin (Vigamox, Alcon), approved April 16, and gatifloxacin (Zymar,Allergan), approved March 31, are the latest therapies for the treatmentof bacterial conjunctivitis caused by susceptible strains of bacteria.At this year's ARVO meeting, ophthalmologists can gain knowledge andclinical information about the fourth-generation fluoroquinolones throughthe various clinical studies that will presented. In a session entitled"New Antibiotics," seven papers will focus exclusively on theclinical studies associated with these two drugs (Program #2114-#2120).